INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celsius Holdings, Inc.

Celsius (NASDAQ: CELH) is facing a securities-fraud investigation by Pomerantz LLP alongside a separate Texas AG probe into whether its high-caffeine drinks were marketed to children/teens and whether safety was misrepresented under the Texas Deceptive Trade Practices Act. On June 4, 2026, shares dropped $2.26 (-7.53%) to close at $27.75 on the investigation news. The developments raise downside risk to product claims and potential legal/regulatory exposure.

Analysis

This is primarily a valuation and channel-risk event, not an immediate earnings event. For a brand-driven beverage name, the first damage usually shows up in retailer behavior before the legal bill does: more cautious shelf resets, heavier promotional spending, and a higher hurdle for new placements. That can quietly compress EBITDA margins even if headline revenue still looks intact for a quarter or two.

The second-order winner is the direct-competition set: MNST, PEP's energy portfolio, and private-label / regional energy brands that can take incremental shelf facings if retailers want to reduce controversy exposure. The biggest risk for CELH is not a lawsuit settlement in isolation; it's a slower, less visible loss of velocity in the younger-skewing convenience channel that forces trade spend to rise just to defend share. If Alani becomes the focal point, the reputational spillover can broaden beyond one SKU family and pressure the whole growth multiple.

Time horizon matters. Over days, this is mostly headline volatility and short-covering risk; over 1-3 months, the key catalyst is whether Texas broadens the probe or other states copy it; over 6-18 months, the question is whether this becomes a durable brand impairment that reduces retailer confidence and acquisition optionality. The contrarian view is that the market may be overpricing legal damages and underpricing the operational drag from a "controversial brand" label. What would falsify the bearish case: no follow-on regulatory action, clean compliance messaging from management, and scanner data showing no deceleration in velocity or shelf space after the next reset.

Key Decisions for Investors

• Short CELH into strength on any relief bounce back toward the high-$20s/low-$30s over the next 1-3 weeks; target a 10-15% downside move if regulatory headlines compound, with a stop if management secures a clean public response and no follow-on state action emerges.
• Pair trade: long MNST / short CELH for a 1-3 month horizon. Thesis is that shelf-space risk and promo intensity should flow to the incumbent with lower controversy exposure; look for 5-8% relative underperformance in CELH if retailer checks soften.
• If options liquidity is adequate, buy CELH 2-4 month put spreads rather than outright puts to cap premium decay; use a strike structure that benefits from a move back through the post-news support area, and abandon if the stock stabilizes and volume data remain firm.
• Do not initiate fresh CELH longs until next quarter's channel checks confirm no velocity hit in convenience and grocery. The thesis is falsified if scanner data and management commentary show share stability despite the probe.